🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

12 recruiting trials

for Extramedullary Multiple Myeloma

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" NCT07382739Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Elranatamab Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM NCT07109323Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: BCMA CART Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease NCT06793475NA2 sites📍 Beijing📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: anti-BCMA/GPRC5D bispecific CAR-T, Apornemin, Carfilzomib, Thalidomide, Dexamethasone Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease NCT06627751Phase 21 site📍 Buffalo Roswell Park Cancer Institute · Tests: Mezigdomide, Carfilzomib, Dexamethasone, Echocardiography, Positron Emission Tomography Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration NCT07003568Phase 11 site📍 Shanghai Beijing GoBroad Hospital · Tests: Dual-targeting BCMA-GPRC5D CAR-T cell infusion GR1803 Injection in Patients With RRMM NCT06952075Phase 21 site📍 Tianjin Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Tests: GR1803 Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma NCT06140966Phase 21 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: Daratumumab, Carfilzomib, Lenalidomide, Dexamethasone, Cisplatin Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma NCT06246162Phase 1, Phase 21 site📍 Nantong Affiliated Hospital of Nantong University · Tests: Lipo-MIT combination regimen Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration NCT07003555Phase 11 site📍 Shanghai Beijing GoBroad Hospital · Tests: Dual-targeting BCMA-CD19 CAR-T cell infusion Registry of Older Patients With Cancer NCT01137825n/a7 sites📍 Boone📍 Chapel Hill📍 Greenville UNC Lineberger Comprehensive Cancer Center Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure European Myeloma Network (EMN) Sample Project NCT06237803n/a41 sites📍 Melbourne📍 Linz📍 Vienna European Myeloma Network B.V. · Tests: storage of biological samples
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy